

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**COALITION FOR AFFORDABLE DRUGS VIII, LLC**

Petitioner,

v.

**THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA**

Patent Owner

---

**Case: IPR2015-01836**

Patent No. 7,932,268

---

**UPDATED LIST OF PATENT OWNER'S EXHIBITS**

## PATENT OWNER'S LIST OF EXHIBITS

Ex. 2001	University of Pennsylvania Patent License Agreement (May 19, 2006)
Ex. 2002	NDA #203858, Sponsor's Background Package For the Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Advisory Committee Briefing Materials (Oct. 17, 2012)
Ex. 2003	ClinicalTrials.gov: Safety, Tolerability, and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor, available at <a href="https://clinicaltrials.gov/ct2/show/NCT01556906?term=NCT01556906&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01556906?term=NCT01556906&amp;rank=1</a>
Ex. 2004	Marina Cuchel <i>et al.</i> , <i>Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia</i> , 356 (2) N. ENG. J. MED. 148-56 (Jan. 11, 2007).
Ex. 2005	U.S. Appl. No. 14/075,483, Amendment and Response to Final Office Action (Nov. 30, 2015)
Ex. 2006	FDA News Release, FDA approves new orphan drug for rare cholesterol disorder, available at <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm</a> (Dec. 26, 2012)
Ex. 2007	Marina Cuchel <i>et al.</i> , <i>Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study</i> , 381 THE LANCET 40-46 (Jan. 5, 2013)
Ex. 2008	Joseph Walker <i>et al.</i> , <i>New Hedge Fund Strategy: Dispute the Patent, Short the Stock</i> , THE WALL STREET JOURNAL (Apr. 7, 2015), available at <a href="http://www.wsj.com/articles/hedgefundmanagerkylebasschallenge-sjazzpharmaceuticalspatent1428417408">http://www.wsj.com/articles/hedgefundmanagerkylebasschallenge-sjazzpharmaceuticalspatent1428417408</a>
Ex. 2009	Intentionally Left Blank
Ex. 2010	Patentee's Observations in reply to the Notice of Opposition by Dr. Evan Stein, European Patent No. 1 725 234

Ex. 2011	The Pink Sheet, <i>MTP inhibitor research discontinued</i> (July 31, 2000)
Ex. 2012	Aegerion Pharmaceuticals, Inc., U.S. Securities and Exchange Commission, Form 10-K (March 2, 2015)
Ex. 2013	Aegerion Pharmaceuticals, Inc., U.S. Securities and Exchange Commission, Form 10-K (March 18, 2013)
Ex. 2014	Aegerion Pharmaceuticals, Inc., Third Quarter 2015 Earnings Conference Call, available at <a href="http://files.shareholder.com/downloads/AEGR/0x0x860375/8F9C1576-D084-454D-BBCF-C656C341E238/AEGR_Q3_15_Slides_Final.pdf">http://files.shareholder.com/downloads/AEGR/0x0x860375/8F9C1576-D084-454D-BBCF-C656C341E238/AEGR_Q3_15_Slides_Final.pdf</a> (Nov. 9, 2015)
Ex. 2015	JUXTAPID label (2012)
Ex. 2016	Center For Drug Evaluation And Research, Application Number 203858Orig1s00, Summary Basis for Regulatory Action (Dec. 21, 2012)
Ex. 2017	Declaration of Nicholas K. Mitrokostas in support of Patent Owner's Motion for <i>Pro Hac Vice</i> Admission of Nicholas K. Mitrokostas Under 37 C.F.R. § 42.10(c)

## **CERTIFICATION OF SERVICE**

The undersigned hereby certifies that the foregoing “**UPDATED LIST OF PATENT OWNER’S EXHIBITS**” was served electronically via e-mail on May 5, 2016 on the following:

Dr. Gregory Gonsalves  
2216 Beacon Lane  
Falls Church, Virginia 22043  
(571) 419-7252  
gonsalves@gonsalveslawfirm.com

Christopher Casieri  
McNeely, Hare & War LLP  
12 Roszel Road, Suite C104  
Princeton, NJ 08540  
(609) 731-3668  
chris@miplaw.com

*Counsel for Petitioner Coalition  
for Affordable Drugs VIII, LLC*

Dated: May 5, 2016

/April E. Weisbruch/

April E. Weisbruch